Johnson & Johnson | August 06, 2020
With leading COVID-19 vaccines in late-stage testing, companies have been inking supply deals with the U.S. government for a quick rollout if their programs succeed. Now, Johnson & Johnson is getting into the act. The pharma giant struck a deal to supply 100 million doses of its candidate, Ad26.COV2.S, if the shot is cleared for use by the FDA. The U.S. government is committing just over $1 billion under the agreement for a price per dose of about $10. That compares with a lower price-per-dose of $4 for AstraZeneca and a higher figure of $19.50 for Pfizer and BioNTech under agreements between those drugmakers and the U.S. government. J&J and AZ have pledged to provide their vaccines under a not-for-profit basis during the pandemic. Under the new J&J deal, which stipulates manufacturing in the U.S., the feds could later buy another 200 million doses under a separate agreement. The company previously won $456 million in funding to support its R&D and manufacturing scale-up, according to a government database.
Ethypharm | June 19, 2021
Ethypharm reports today that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use.
On account of the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the main 5 European markets after shutting, which is expected in the second half of 2021. Ethypharm will likewise profit with an enlarged portfolio of great hospital injectable products and a rich pipeline of R&D projects, which fit perfectly with its current Critical Care franchise.
"Altan Pharma's product portfolio and geographic coverage are highly complementary to those of Ethypharm. We look forward to welcoming Altan Pharma's teams, as we are convinced that together, our product portfolio, our R&D and our industrial expertise, will put us in a stronger position to fulfil our commitment to the patients we serve", said Bertrand Deluard, CEO of Ethypharm. "The Altan Pharma acquisition is an important milestone in Ethypharm's transformation journey. By entering the Spanish market and reinforcing our Critical Care franchise, Ethypharm proves once again its ability to execute on its long-term growth ambition."
"Joining an established European specialty pharmaceutical company, with a strong direct commercial presence in Europe beyond Spain and in major growth territories for injectable medicines, will be a booster for the international expansion of Altan Pharma's product portfolio" said Guillermo Herrera, CEO of Altan Pharma. "Since its inception in 1998, Altan Pharma has been committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers."
About Altan Pharma
Altan Pharma is a specialty pharmaceutical company that develops, manufactures and markets injectable medications for the hospital and other provider segments. Altan is a premier, global injectable drug company that is committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers.
Altan Pharma currently markets a portfolio of over 40 injectable medications used in pain and anaesthesia, epilepsy, oncology, anti-infectives, cardiovascular, and gynecology and is developing an attractive portfolio of additional products in these areas.
Fiercepharma | August 27, 2020
GlaxoSmithKline has a goal when it comes to vaccine awareness: Boost education enough so that when people turn 50, they recognize age-recommended vaccines as automatically as they know it's time to get a colonoscopy. To work toward that benchmark, the company debuted its first general vaccine awareness campaign in the U.S. this month. The multichannel effort keys in on life moments, with the message that they’re made possible by vaccines. The “Brought to You by Vaccines” campaign includes TV, digital, social media and public relations and will run through mid-2021.